16.79

2.47% -0.425

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $16.79, with a volume of 380.69K. It is down -2.47% in the last 24 hours and down -16.53% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Previous Close:

$17.21

Open:

$17.23

24h Volume:

380.69K

Relative Volume:

0.85

Market Cap:

$558.68M

Revenue:

$219.79M

Net Income/Loss:

$-57.47M

P/E Ratio:

-7.807

EPS:

-2.15

Net Cash Flow:

$-19.25M

1W Performance:

-13.26%

1M Performance:

-16.53%

6M Performance:

-49.58%

1Y Performance:

-31.27%

1-Day Range:

$16.67

$17.34

1-Week Range:

$15.70

$19.67

52-Week Range:

$15.70

$35.84

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1153)

Industry

Diagnostics & Research (56)

Phone

866-788-9007

Address

505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX

Employee

761

Twitter

@castlebio

Next Earnings Date

2024-11-04

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	16.79	558.68M	219.79M	-57.47M	-19.25M	-2.15
TMO Thermo Fisher Scientific Inc	403.13	159.89B	42.90B	6.52B	6.72B	17.05
DHR Danaher Corp	189.73	142.45B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	491.70	37.95B	3.93B	894.97M	837.70M	10.82
A Agilent Technologies Inc	106.93	30.97B	6.53B	1.26B	1.31B	4.35
IQV Iqvia Holdings Inc	148.99	26.72B	15.50B	1.33B	2.16B	7.34

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

06:15 AM

Castle Biosciences confirms UM test’s efficacy - Investing.com

06:15 AM

May 09, 2025

Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com South Africa

May 09, 2025

Castle Biosciences to buy Previse - MSN

May 09, 2025

Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Risk Prediction | CSTL Stock News - GuruFocus

May 09, 2025

Castle Biosciences Reports Independent Validation of DecisionDx-UM Test with PRAME Gene Expression Data at ARVO 2025 - Nasdaq

May 09, 2025

Real-World Study Confirms Long-Term Performance of - GlobeNewswire

May 09, 2025

Texas public company to acquire Baltimore cancer diagnostic firm - The Business Journals

May 09, 2025

May 07, 2025

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025

Castle Biosciences (CSTL) Champions Skin Cancer Awareness Initiatives | CSTL Stock News - GuruFocus

May 07, 2025

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

May 06, 2025

Castle Biosciences (CSTL) Receives Price Target Adjustment by Canaccord Genuity | CSTL Stock News - GuruFocus

May 06, 2025

Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | C - GuruFocus

May 06, 2025

Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | CSTL Stock News - GuruFocus

May 06, 2025

Castle Biosciences to Acquire Previse - FinSMEs

May 06, 2025